Carna Biosciences, Inc. reported consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company's net sales were JPY 211 million against JPY 196 million a year ago. Operating loss was JPY 188 million against JPY 113 million a year ago. Ordinary loss was JPY 191 million against JPY 113 million a year ago. Loss attributable to owners of parent was JPY 194 million against JPY 118 million a year ago. Basic loss per share was JPY 20.36 against JPY 12.80 a year ago. Loss before income taxes was JPY 193,506,000 against JPY 118,059,000 a year ago.

For full year ending December 31, 2018, the consolidated company expects net sales of JPY 1,190 million, operating loss of JPY 679 million, ordinary loss of JPY 694 million, loss attributable to owners of parent of JPY 758 million or JPY 79.39 per share.